Monographie - Daunorubicin hydrochloride

Viimeisin päivitys :
08/05/2024

Daunorubicin hydrochloride

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cerubidin	Irlanti, Iso-Britannia, Norja, Ruotsi, Tanska
Cerubidine	Belgia, Chile, Hollanti, Kanada, Luxemburg, Marokko, Ranska, Sveitsi, Tunisia, Turkki, Yhdysvallat
D Blastin	Marokko
Daunac	Kolumbia
Daunobin	Intia
Daunoblastin	Itävalta, Saksa
Daunoblastina	Espanja, Iran, Italia, Kreikka, Saudi-Arabia, Unkari, Venezuela
Daunocin	Intia, Malesia, Marokko
Daunogobbi	Argentiina
Daunomed	Intia, Marokko
Daunomycin	Intia
Daunoplus	Intia
Daunorubicin	Australia, Iso-Britannia, Kanada, New Zealand, Yhdysvallat
Daunorubicina	Chile, Ecuador, Kolumbia, Marokko, Meksiko
Daunorubitec	Intia
Daunoside	Intia
Daunotec	Intia, Venezuela
Daurocina	Chile
Epodoxo	Marokko
Maxidauno	Argentiina, Ecuador
Oncodaunotec	Kolumbia
Rubilem	Meksiko
Runabicon	Kolumbia, Meksiko
Zuleb	Meksiko

Viitteet : Daunorubicin hydrochloride

	Tyyppi	Julkaisu
3	Lehti	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Lehti	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Lehti	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Lehti	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148	Lehti	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150	Lehti	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Lehti	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	Lehti	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Lehti	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Lehti	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Lehti	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Lehti	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
492	Lehti	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
632	Lehti	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
643	Lehti	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
686	Lehti	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
905	Lehti	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1265	Lehti	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1284	Lehti	Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol 1981 ; 34: 131-134.
1410	Lehti	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1520	Laboratorio	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Lehti	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1897	Lehti	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1982	Lehti	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Lehti	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438	Lehti	Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Laboratorio	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3604	Laboratorio	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3668	Laboratorio	Dexamethasone - Summary of Product Characteristics Hospira 2015

Mentions Légales